Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 17, 2017. The document serves as a transaction notification regarding a specific corporate action involving the company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a single transaction event:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Acquisition of ADSs via dividend reinvestment under the US Deferred Performance Share Plan.
- Transaction Date: July 14, 2017.
- Exchange: New York Stock Exchange (XNYS).
- Price: $42.50 per ADS.
- Total Volume: 358.320 ADSs (comprising 352.882 and 5.438 units).
Material Changes
The filing does not provide comparative financial data or material changes to the company's overall financial position versus prior periods. The only change reported is the specific acquisition of shares by a Person Closely Associated (PCA) with a Principal Director/Manager (PDMR).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a mandatory disclosure of a transaction involving Mr. D E Troy, SVP & General Counsel, who acquired shares following the reinvestment of dividends paid on July 13, 2017.
Investor Verification Points
- Verify the total number of ADSs held by Mr. D E Troy post-transaction to assess insider ownership levels.
- Confirm the dividend reinvestment terms of the US Deferred Performance Share Plan.
- Check the market price of GSK ADSs on July 14, 2017, to validate the transaction price of $42.50.